Advertisement

Tumor Biology

, Volume 36, Issue 12, pp 9961–9968 | Cite as

The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma

  • Yuan Yuan
  • Zhulin Yang
  • Xiongying Miao
  • Daiqiang Li
  • Ziru Liu
  • Qiong Zou
Research Article

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with intrinsic resistance to cytotoxic agents. The molecular mechanisms associated with high malignancy and resistance to chemotherapy and radiotherapy have not been fully elucidated. This study investigated the clinicopathological significances of frequently rearranged in advanced T-cell lymphomas-1 (FRAT1) and ATP-binding cassette subfamily G member 2 (ABCG2) expression in PDAC. FRAT1 and ABCG2 protein expression in 106 PDAC, 35 peritumoral tissues, 55 benign pancreatic tissues, and 13 normal pancreatic tissues was measured by immunohistochemistry. FRAT1 and ABCG2 protein was overexpressed in PDAC tumors compared to peritumoral tissues, benign pancreatic tissues, and normal pancreatic tissues (P < 0.01). The percentage of cases with positive FRAT1 and ABCG2 overexpression was significantly higher in PDAC patients with poor differentiation, lymph node metastasis, invasion, and TNM stage III/IV disease than in patients with well-differentiated tumor, no lymph node metastasis and invasion, and TNM stage I/II disease (P < 0.05 or P < 0.01). In pancreatic tissues with benign lesions, tissues with positive FRAT1 and ABCG2 protein expression exhibited dysplasia or intraepithelial neoplasia. Kaplan-Meier survival analysis showed that PDAC patients with positive FRAT1 and ABCG2 expression survived significantly shorter than patients with negative FRAT1 and ABCG2 expression (P < 0.05 or P < 0.001). Cox multivariate analysis revealed that positive FRAT1 and ABCG2 expression was an independent poor prognosis factor in PDAC patients. FRAT1 and ABCG2 overexpression is associated with carcinogenesis, progression, and poor prognosis in patients with PDAC.

Keywords

Pancreatic ductal adenocarcinoma Dysplasia Pancreatic intraepithelial neoplasia FRAT1 ABCG2 Immunohistochemistry 

Notes

Conflict of interest

None

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefPubMedGoogle Scholar
  3. 3.
    Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17.CrossRefPubMedGoogle Scholar
  4. 4.
    Löhr M. Is it possible to survive pancreatic cancer? Nat Clin Pract Gastroenterol Hepatol. 2006;3:236–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Cui J, Jiang W, Wang S, Wang L, Xie K. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des. 2012;18:2464–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Schober M, Jesenofsky R, Faissner R, et al. Desmoplasia and chemoresistance in pancreatic cancer. Cancers (Basel). 2014;6:2137–54.CrossRefGoogle Scholar
  7. 7.
    Freemantle SJ, Portland HB, Ewings K, et al. Characterization and tissue-specific expression of human GSK-3-binding proteins FRATl and FRAT2. Gene. 2002;291:17–27.CrossRefPubMedGoogle Scholar
  8. 8.
    Yost C, Farr GH, Pierce SB, et al. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell. 1998;93:1031–41.CrossRefPubMedGoogle Scholar
  9. 9.
    Guo G, Kuai D, Cai S, et al. Knockdown of FRAT1 expression by RNA interference inhibits human glioblastoma cell growth, migration and invasion. PLoS ONE. 2013;8, e61206.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zhang Y, Yu JH, Lin XY, et al. Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer. Virchows Arch. 2011;459:255–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang Y, Liu S, Zhu H, et al. FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma. Int J Cancer. 2008;123:561–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Wang Y, Hewitt SM, Liu S, et al. Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours. Br J Cancer. 2006;94:686–91.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Saitoh T, Katoh M. FRAT1 and FRAT2, clustered in human chromosome 10q24.1 region, are up-regulated in gastric cancer. Int J Oncol. 2001;19:311–5.PubMedGoogle Scholar
  14. 14.
    Jonkers J, Weening JJ, van der Valk M, et al. Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression. Oncogene. 1999;18:5982–90.CrossRefPubMedGoogle Scholar
  15. 15.
    Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab. 2010;11:603–17.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sarkadi B, Ozvegy-Laczka C, Német K, Váradi A. ABCG2 - a transporter for all seasons. FEBS Lett. 2004;567:116–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Campa D, Müller P, Edler L, et al. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer. 2012;131:2920–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Omran OM. The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas. J Environ Pathol Toxicol Oncol. 2012;31:367–76.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhang G, Wang Z, Luo W, et al. Expression of potential cancer stem cell marker ABCG2 is associated with malignant behaviors of hepatocellular carcinoma. Gastroenterol Res Pract. 2013;2013:782581.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Jiang Y, He Y, Li H, et al. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Gastric Cancer. 2012;15:440–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang X, Xia B, Liang Y, et al. Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival. Cancer Biomark. 2013;13:81–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Mohelnikova-Duchonova B, Brynychova V, Oliverius M, et al. Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. Pancreas. 2013;42:707–16.CrossRefPubMedGoogle Scholar
  23. 23.
    Liu DC, Yang ZL, Jiang S. Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Pathol Oncol Res. 2011;17:859–66.CrossRefPubMedGoogle Scholar
  24. 24.
    Olsen PA, Solberg NT, Lund K, et al. Implications of targeted genomic disruption of β-catenin in BxPC-3 pancreatic adenocarcinoma cells. PLoS ONE. 2014;9, e115496.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zhi X, Tao J, Xie K, et al. MUC4-induced nuclear translocation of β-catenin: a novel mechanism for growth, metastasis and angiogenesis in pancreatic cancer. Cancer Lett. 2014;346:104–13.CrossRefPubMedGoogle Scholar
  26. 26.
    Bilic J, Huang YL, Davidson G, et al. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science. 2007;316:1619–22.CrossRefPubMedGoogle Scholar
  27. 27.
    Van Amerongen R, Nawijn MC, Lambooij JP, et al. Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways. Oncogene. 2010;29:93–104.CrossRefPubMedGoogle Scholar
  28. 28.
    Mohan A, Kandalam M. Ram kumar HL, et al. Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma. Br J Ophthlmol. 2006;90:889–93.CrossRefGoogle Scholar
  29. 29.
    Szczuraszek K, Materna V, Halon A, et al. Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin’s lymphomas. Oncol Rep. 2009;22:1315–23.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yuan Yuan
    • 1
  • Zhulin Yang
    • 2
  • Xiongying Miao
    • 2
  • Daiqiang Li
    • 3
  • Ziru Liu
    • 2
  • Qiong Zou
    • 1
  1. 1.Department of Pathology, Third Xiangya HospitalCentral South UniversityChangshaPeople’s Republic of China
  2. 2.Research Laboratory of Hepatobiliary Diseases, Second Xiangya HospitalCentral South UniversityChangshaPeople’s Republic of China
  3. 3.Department of Pathology, Second Xiangya HospitalCentral South UniversityChangshaPeople’s Republic of China

Personalised recommendations